Our combination strategy of TPME remodeling synergized with immune‐metabolic blockade can establish an inflammatory tumor immune niche via disrupting the IDO1/Kyn/AhR axis‐mediated immune escape, which exerts effective tumoricidal immune activity to inhibit postsurgical ccRCC recurrence. The gene discussed is AHR; the disease is nonpapillary renal cell carcinoma.